Skip to content
Putting patients first: Why PBM reform must ensure that middlemen pass along 100% of rebates
This is the first in a series of Bio.News articles looking at the need for pharmacy benefit manager (PBM) reform through the lens of […]
CMS must address Part D plan abuse of IRA provisions designed to protect patient access
The Biotechnology Innovation Organization (BIO) has once again requested that the Centers for Medicare & Medicaid Services (CMS) take steps to protect patient access,
CMS must address Part D plan abuse of IRA provisions designed to protect patient access Read More »
Open enrollment can be a ‘House of Horrors’: 4 monsters for patients to beware
October is the scariest time of year. Young goblins walk the streets demanding treats, local haunted houses are packed full of fright-chasing teens, and
Open enrollment can be a ‘House of Horrors’: 4 monsters for patients to beware Read More »
Skyrocketing 340B program spending must prompt more hospital accountability
The 340B program grew by 24% in 2023, according to new figures from the government’s Health Resources and Services Administration. Sales at discounted prices
Skyrocketing 340B program spending must prompt more hospital accountability Read More »
Development of non-opioid pain medicines threated by IRA’s ‘pill penalty’
The search for safer, effective replacements for opioids is a critical public health priority, but that effort is being undermined by the Inflation Reduction
Development of non-opioid pain medicines threated by IRA’s ‘pill penalty’ Read More »
As Medicare open enrollment nears, seniors will face difficult choices despite CMS’ rosy assessment
Prescription drug coverage in Medicare will see sweeping changes – for both health plans and for the millions of American seniors they serve –
As Medicare open enrollment nears, ‘M3P’ and the out-of-pocket cap loom large
Medicare beneficiaries will soon need to begin thinking about their coverage for 2025, with the open enrollment period opening on Oct. 15. The next
As Medicare open enrollment nears, ‘M3P’ and the out-of-pocket cap loom large Read More »
CMS listens to BIO and understands proposed policies could have harmed patients, innovation
A new suite of rules governing drug rebates in Medicaid has been finalized, removing months of uncertainty about whether the Centers for Medicare and
BIO’s view: Sanders’ latest attack on innovation misses realities about groundbreaking drugs
Yesterday, Sen. Bernie Sanders held a meeting about the new class of groundbreaking diabetes and weight-loss medicines. Next week, he will hold a hearing
Four key facts ahead of tomorrow’s drug pricing hearing
The Senate Finance Committee will hold a hearing tomorrow on “understanding the benefits of the Inflation Reduction Act.” Expect to hear a lot of rhetoric
Four key facts ahead of tomorrow’s drug pricing hearing Read More »